Chimeric 14-3-3 Proteins for Unraveling Interactions with Intrinsically Disordered Partners

Overview

Journal Sci Rep

Specialty Science

Date 2017 Sep 22

PMID 28931924

Citations 10

Authors

Nikolai N Sluchanko

Kristina V Tugaeva

Sandra J Greive

Alfred A Antson

Affiliations

Soon will be listed here.

Abstract

In eukaryotes, several "hub" proteins integrate signals from different interacting partners that bind through intrinsically disordered regions. The 14-3-3 protein hub, which plays wide-ranging roles in cellular processes, has been linked to numerous human disorders and is a promising target for therapeutic intervention. Partner proteins usually bind via insertion of a phosphopeptide into an amphipathic groove of 14-3-3. Structural plasticity in the groove generates promiscuity allowing accommodation of hundreds of different partners. So far, accurate structural information has been derived for only a few 14-3-3 complexes with phosphopeptide-containing proteins and a variety of complexes with short synthetic peptides. To further advance structural studies, here we propose a novel approach based on fusing 14-3-3 proteins with the target partner peptide sequences. Such chimeric proteins are easy to design, express, purify and crystallize. Peptide attachment to the C terminus of 14-3-3 via an optimal linker allows its phosphorylation by protein kinase A during bacterial co-expression and subsequent binding at the amphipathic groove. Crystal structures of 14-3-3 chimeras with three different peptides provide detailed structural information on peptide-14-3-3 interactions. This simple but powerful approach, employing chimeric proteins, can reinvigorate studies of 14-3-3/phosphoprotein assemblies, including those with challenging low-affinity partners, and may facilitate the design of novel biosensors.

Citing Articles

Proximity-enhanced cysteine-histidine crosslinking for elucidating intrinsically disordered and other protein complexes.

Wu Q, van den Wildenberg S, Brzoskowski J, van den Oetelaar M, Verhoef C, Genet S Chem Sci. 2025; 16(8):3523-3535.

PMID: 39850253 PMC: 11752056. DOI: 10.1039/d4sc07419j.

Fragment-Based Interrogation of the 14-3-3/TAZ Protein-Protein Interaction.

Andlovic B, Valenti D, Centorrino F, Picarazzi F, Hristeva S, Hiltmann M Biochemistry. 2024; 63(17):2196-2206.

PMID: 39172504 PMC: 11375770. DOI: 10.1021/acs.biochem.4c00248.

The Integration of Proteome-Wide PTM Data with Protein Structural and Sequence Features Identifies Phosphorylations that Mediate 14-3-3 Interactions.

Egbert C, Warr L, Pennington K, Thornton M, Vaughan A, Ashworth S J Mol Biol. 2022; 435(2):167890.

PMID: 36402225 PMC: 10099770. DOI: 10.1016/j.jmb.2022.167890.

The Amyloid Fibril-Forming β-Sheet Regions of Amyloid β and α-Synuclein Preferentially Interact with the Molecular Chaperone 14-3-3ζ.

Williams D, Thorn D, Dobson C, Meehan S, Jackson S, Woodcock J Molecules. 2021; 26(20).

PMID: 34684701 PMC: 8538830. DOI: 10.3390/molecules26206120.

Hierarchized phosphotarget binding by the seven human 14-3-3 isoforms.

Gogl G, Tugaeva K, Eberling P, Kostmann C, Trave G, Sluchanko N Nat Commun. 2021; 12(1):1677.

PMID: 33723253 PMC: 7961048. DOI: 10.1038/s41467-021-21908-8.

References

Muslin A, Tanner J, Allen P, Shaw A . Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell. 1996; 84(6):889-97. DOI: 10.1016/s0092-8674(00)81067-3. View

Richter A, Rose R, Hedberg C, Waldmann H, Ottmann C . An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction. Chemistry. 2012; 18(21):6520-7. DOI: 10.1002/chem.201103761. View

Goldschmidt L, Cooper D, Derewenda Z, Eisenberg D . Toward rational protein crystallization: A Web server for the design of crystallizable protein variants. Protein Sci. 2007; 16(8):1569-76. PMC: 2203352. DOI: 10.1110/ps.072914007. View

Tinti M, Madeira F, Murugesan G, Hoxhaj G, Toth R, Mackintosh C . ANIA: ANnotation and Integrated Analysis of the 14-3-3 interactome. Database (Oxford). 2014; 2014:bat085. PMC: 3914767. DOI: 10.1093/database/bat085. View

Woodcock J, Murphy J, Stomski F, Berndt M, Lopez A . The dimeric versus monomeric status of 14-3-3zeta is controlled by phosphorylation of Ser58 at the dimer interface. J Biol Chem. 2003; 278(38):36323-7. DOI: 10.1074/jbc.M304689200. View

Reinhardt H, Yaffe M . Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol. 2013; 14(9):563-80. DOI: 10.1038/nrm3640. View

Rose R, Rose M, Ottmann C . Identification and structural characterization of two 14-3-3 binding sites in the human peptidylarginine deiminase type VI. J Struct Biol. 2012; 180(1):65-72. DOI: 10.1016/j.jsb.2012.05.010. View

Asaoka Y, Kanai F, Ichimura T, Tateishi K, Tanaka Y, Ohta M . Identification of a suppressive mechanism for Hedgehog signaling through a novel interaction of Gli with 14-3-3. J Biol Chem. 2009; 285(6):4185-4194. PMC: 2823557. DOI: 10.1074/jbc.M109.038232. View

Yaffe M, Smerdon S . PhosphoSerine/threonine binding domains: you can't pSERious?. Structure. 2001; 9(3):R33-8. DOI: 10.1016/s0969-2126(01)00580-9. View

10.

Taoka K, Ohki I, Tsuji H, Furuita K, Hayashi K, Yanase T . 14-3-3 proteins act as intracellular receptors for rice Hd3a florigen. Nature. 2011; 476(7360):332-5. DOI: 10.1038/nature10272. View

11.

Li Z, Tang J, Guo F . Identification of 14-3-3 Proteins Phosphopeptide-Binding Specificity Using an Affinity-Based Computational Approach. PLoS One. 2016; 11(2):e0147467. PMC: 4734684. DOI: 10.1371/journal.pone.0147467. View

12.

Gardino A, Smerdon S, Yaffe M . Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol. 2006; 16(3):173-82. DOI: 10.1016/j.semcancer.2006.03.007. View

13.

Xu C, Jin J, Bian C, Lam R, Tian R, Weist R . Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat tumbler lock. Sci Signal. 2012; 5(226):ra39. DOI: 10.1126/scisignal.2002979. View

14.

Bustos D, Iglesias A . Intrinsic disorder is a key characteristic in partners that bind 14-3-3 proteins. Proteins. 2006; 63(1):35-42. DOI: 10.1002/prot.20888. View

15.

Aitken A . 14-3-3 proteins: a historic overview. Semin Cancer Biol. 2006; 16(3):162-72. DOI: 10.1016/j.semcancer.2006.03.005. View

16.

Ding S, Zhou R, Zhu Y . Structure of the 14-3-3ζ-LKB1 fusion protein provides insight into a novel ligand-binding mode of 14-3-3. Acta Crystallogr F Struct Biol Commun. 2015; 71(Pt 9):1114-9. PMC: 4555915. DOI: 10.1107/S2053230X15012595. View

17.

Ding S, Zhou R, Zhu Y . Crystallization and preliminary crystallographic analysis of the chimeric protein LKB1-14-3-3ζ. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013; 69(Pt 12):1371-3. PMC: 3855723. DOI: 10.1107/S1744309113029230. View

18.

Sluchanko N, Sudnitsyna M, Seit-Nebi A, Antson A, Gusev N . Properties of the monomeric form of human 14-3-3ζ protein and its interaction with tau and HspB6. Biochemistry. 2011; 50(45):9797-808. DOI: 10.1021/bi201374s. View

19.

Mori M, Vignaroli G, Cau Y, Dinic J, Hill R, Rossi M . Discovery of 14-3-3 protein-protein interaction inhibitors that sensitize multidrug-resistant cancer cells to doxorubicin and the Akt inhibitor GSK690693. ChemMedChem. 2014; 9(5):973-83. DOI: 10.1002/cmdc.201400044. View

20.

Henriksson M, Francis M, Peden A, Aili M, Stefansson K, Palmer R . A nonphosphorylated 14-3-3 binding motif on exoenzyme S that is functional in vivo. Eur J Biochem. 2002; 269(20):4921-9. DOI: 10.1046/j.1432-1033.2002.03191.x. View